A district court judge’s ruling that the US Food and Drug Administration could not prevent two stem cell clinics from administering unapproved stromal vascular stem cell treatments shows how difficult it is for the agency to regulate novel products.
Eva Temkin, a partner at King & Spalding, noted that one of the problems for the FDA is that it...